Study of people with LMNA or EMD gene mutations
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study follows people who have a confirmed harmful (pathogenic) mutation in the LMNA and/or EMD gene. It aims to better understand these conditions through regular follow-up and health information collection, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed harmful mutation in the LMNA and/or EMD gene
- You are able to have regular follow-up visits in France
- You are willing to sign the study consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what influences the course of a muscle disease caused by an LMNA genetic change (a type of laminopathy). It may help researchers better understand the disease and how it affects muscle and sometimes breathing or heart function.
This study looks for early signs of ALS in people with genetic risk, healthy controls, and people with early symptoms. It aims to find markers that could help diagnose ALS sooner.
This study tries to find genetic causes for rare diseases that are not yet understood. It uses a national rare-disease data bank and collects consent from patients and sometimes close family members.
This study follows children with LAMA2-related muscular dystrophy to learn how the condition changes over time. It does not test a new treatment, but helps researchers understand the disease better.
This study follows people with LAMA2-related muscular dystrophy or SELENON-related myopathy over 5 years to understand how the condition changes over time. It may help you by tracking your disease progression and contributing to future research.
This study follows people with LAMA2-related muscular dystrophy over time to better understand the condition. It may help with future treatments by learning more about how the disease progresses.
Hear when a new Laminopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.